Inactive Instrument

QSAM Biosciences, Inc.

QSAM

US74738N2027

Biotechnology & Medical Research

Q2Power Technologies, Inc. Names Scott W. Whitney to the Board of Directors

March 23, 2016 at 10:12 am

On March 18, 2016, Q2Power Technologies, Inc. named Scott W. Whitney to the Company's Board of Directors. Mr. Whitney is currently CEO of Liberty Tire Recycling Co.

Latest news about QSAM Biosciences, Inc.

Telix Pharmaceuticals (Us) Inc. completed the acquisition of QSAM Biosciences, Inc. from Checkmate Capital Group LLC, Strategic Planning Assets Limited and others.	05-02	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Telix Pharmaceuticals Limited signed a non-binding term sheet to acquire QSAM Biosciences, Inc. for $33.1 million.	11-13	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding	28/09/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	14/06/23	CI
QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center	23/05/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
QSAM Biosciences, Inc. Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam	26/04/23	CI
QSAM Biosciences Inc. Opens Enrollment of Second Cohort of Patients in its Phase 1 Study of CycloSam®? Targeting Metastatic Bone Cancer	05/04/23	CI
QSAM Biosciences, Inc. announced that it has received $3 million in funding	30/03/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
QSAM Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of Cyclosam(R) Targeting Metastatic Bone Cancer	08/03/23	CI
QSAM Biosciences, Inc. Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	28/02/23	CI
QSAM Biosciences, Inc. Recruits the Ellis Fischel Cancer Center At the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam for Bone Cancer	22/02/23	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
QSAM Biosciences, Inc Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer	26/10/22	CI
QSAM Biosciences, Inc. announced a financing transaction	29/09/22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam	13/07/22	CI
QSAM Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
QSAM Biosciences, Inc. Announces the First Patient Commenced Treatment in Its Clinical Trial Evaluating Cyclosam® in Patients with Metastatic Bone Cancer	28/04/22	CI
QSAM Biosciences Inc. Receives Japanese Patent for Its Clinical Stage Radiopharmaceutical Drug Candidate, Cyclosam	12/04/22	CI

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Companyâs technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research

QSAM Biosciences, Inc.

Equities

QSAM

US74738N2027

Biotechnology & Medical Research

Q2Power Technologies, Inc. Names Scott W. Whitney to the Board of Directors

Latest news about QSAM Biosciences, Inc.

Chart QSAM Biosciences, Inc.

Company Profile

Sector Other Biotechnology & Medical Research